File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

TitleTransplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Authors
KeywordsCOVID-19
ACE2 negative
Mesenchymal stem cells
Cell transplantation
Immunomodulation
Function recovery
Issue Date2020
PublisherBuck Institute for Age Research. The Journal's web site is located at http://www.aginganddisease.org
Citation
Aging and Disease, 2020, v. 11 n. 2, p. 216-228 How to Cite?
AbstractA coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.
Persistent Identifierhttp://hdl.handle.net/10722/281329
ISSN
2019 Impact Factor: 5.402
2015 SCImago Journal Rankings: 1.542
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeng, Z-
dc.contributor.authorZhu, R-
dc.contributor.authorHou, W-
dc.contributor.authorFeng, Y-
dc.contributor.authorYang, Y-
dc.contributor.authorHan, Q-
dc.contributor.authorShan, G-
dc.contributor.authorMeng, F-
dc.contributor.authorDu, D-
dc.contributor.authorWang, S-
dc.contributor.authorFan, J-
dc.contributor.authorWang, W-
dc.contributor.authorDeng, L-
dc.contributor.authorShi, H-
dc.contributor.authorLi, H-
dc.contributor.authorHu, Z-
dc.contributor.authorZhang, F-
dc.contributor.authorGao, J-
dc.contributor.authorLiu, H-
dc.contributor.authorLi, X-
dc.contributor.authorZhao, Y-
dc.contributor.authorYin, K-
dc.contributor.authorHe, X-
dc.contributor.authorGao, Z-
dc.contributor.authorWang, Y-
dc.contributor.authorYang, B-
dc.contributor.authorJin, R-
dc.contributor.authorStambler, I-
dc.contributor.authorLim, LW-
dc.contributor.authorSu, H-
dc.contributor.authorMoskalev, A-
dc.contributor.authorCano, A-
dc.contributor.authorChakrabarti, S-
dc.contributor.authorMin, K-
dc.contributor.authorEllison-Hughes, G-
dc.contributor.authorCaruso, C-
dc.contributor.authorJin, K-
dc.contributor.authorZhao, RC-
dc.date.accessioned2020-03-11T07:31:15Z-
dc.date.available2020-03-11T07:31:15Z-
dc.date.issued2020-
dc.identifier.citationAging and Disease, 2020, v. 11 n. 2, p. 216-228-
dc.identifier.issn2152-5250-
dc.identifier.urihttp://hdl.handle.net/10722/281329-
dc.description.abstractA coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.-
dc.languageeng-
dc.publisherBuck Institute for Age Research. The Journal's web site is located at http://www.aginganddisease.org-
dc.relation.ispartofAging and Disease-
dc.subjectCOVID-19-
dc.subjectACE2 negative-
dc.subjectMesenchymal stem cells-
dc.subjectCell transplantation-
dc.subjectImmunomodulation-
dc.subjectFunction recovery-
dc.titleTransplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia-
dc.typeArticle-
dc.identifier.emailLim, LW: limlw@hku.hk-
dc.identifier.authorityLim, LW=rp02088-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.14336/AD.2020.0228-
dc.identifier.pmid32257537-
dc.identifier.pmcidPMC7069465-
dc.identifier.scopuseid_2-s2.0-85082424283-
dc.identifier.hkuros309432-
dc.identifier.volume11-
dc.identifier.issue2-
dc.identifier.spage216-
dc.identifier.epage228-
dc.identifier.isiWOS:000520029200001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats